Claim Ledger
67% answered
Did management answer the analysts?
12 analyst questions audited, 3 evaded or deflected.
View Claim Ledger →Acutaas Chemicals Ltd — Q4 FY26
Acutaas Chemicals delivered a stellar Q4 FY26 with revenue of 432.8 cr (+40.3% YoY) and EBITDA of 183.5 cr (margin 42.4%, +1487 bps YoY), driven by strong CDMO ramp-up, portfolio reshuffling, and operating leverage.
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Acutaas Chemicals delivered a stellar Q4 FY26 with revenue of 432.8 cr (+40.3% YoY) and EBITDA of 183.5 cr (margin 42.4%, +1487 bps YoY), driven by strong CDMO ramp-up, portfolio reshuffling, and operating leverage. PAT more than doubled to 134.3 cr. Management guided for 25% revenue growth in FY27 and stable EBITDA margins, supported by battery electrolyte additive commercialization, four new CDMO products in validation, and recovery in semiconductor chemicals (BFC). The South Korea JV (Indicam) is on track for H2 CY26 commissioning. Key risk: global supply chain disruptions from Gulf conflict could pressure raw material costs and margins.
Promises0 met · 1 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Promises
1 promise
Promise Tracker
0 delivered, 0 close, 1 missed.
View Promises →
Risks
4 risks
Risk Intelligence
Global supply chain disruptions from Gulf conflict
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Advanced Pharma Intermediates Revenue
392.4 cr
+43.9% YoY
Driven by CDMO business and portfolio reshuffling; sequential growth after first nine months.
Specialty Chemicals Revenue
40.3 cr
+12.3% YoY
Commodity decline offset by strong BFC recovery; includes battery chemicals.
CDMO Pipeline Validation
4 products
flat
Four new CDMO products validated; each with peak revenue potential of 50-200 cr.
Battery Electrolyte Additive Capacity
2,000 MTPA
flat
Fully contracted for next 3 years; production started, meaningful contribution expected in FY27.
What Changed vs Last Quarter
NEW
25% revenue growth in FY27
Management guided for 25% year-on-year revenue growth in FY27, consistent with historical performance.
NEW
Capex of ~₹90 cr in FY27 (spillover + maintenance)
FY27 capex includes ~₹50 cr spillover from FY26 (electrolyte additive and pilot plant) and ~₹40 cr maintenance capex.
UPDATED
EBITDA margin similar to FY26 level
Management expects EBITDA margin to remain at similar levels as FY26 (around 35-36%), driven by product mix.
UPDATED
CDMO revenue target of ₹1,000 cr by FY28
The CDMO business is expected to reach ₹1,000 cr in revenue by FY28, backed by long-term contracts and pipeline.
DROPPED
FY26 revenue growth guidance raised to ~30%
Management revised revenue growth guidance from 25% to around 30% for FY26, based on strong order book.
DROPPED
Battery chemicals commercial production by Q4 FY26
Electrolyte additive plant inaugurated Jan 19, 2026; trial production in Q4, commercial ramp-up from Q1 FY27.
NEW RISK
Global supply chain disruptions from Gulf conflict
Ongoing conflict in the Gulf region has disrupted feedstock supply chains and pushed raw material prices higher, potentially impacting margins.
NEW RISK
Goodwill recoverability from Indicam JV
Analyst raised concern about ₹48 cr goodwill added for Indicam JV, which has no revenue yet. Management expressed confidence but provided no specific recovery timeline.
NEW RISK
Seasonality and Q1 weakness
Q1 is historically the weakest quarter (H1 ~40% of revenue). Despite CDMO ramp-up, management expects similar seasonality in FY27.
NEW RISK
Technology shift to sodium-ion batteries
Analyst asked about risk from sodium-ion battery adoption. Management downplayed near-term impact but acknowledged potential long-term shift.
RISK GONE
Execution delays in battery and semiconductor verticals
Pilot plant capex delayed due to equipment arrival; second phase of battery chemicals capex spills into FY27. Any further delays could impact revenue ramp-up.
RISK GONE
Product concentration risk in CDMO
Top CDMO product (oncology) drives a significant portion of growth. Analyst raised concern about concentration; management acknowledged but did not provide specific derisking timeline.
RISK GONE
Chinese competition in intermediates
Chinese competitors remain a threat across segments. Management claims strong chemistry capabilities and market leadership in key products, but competition could pressure pricing.
RISK GONE
Working capital days elevated
Net working capital days at 111, with debtor days at 100. Management considers 110 days standard, but any deterioration could strain cash flows.
Fast read
Guidance and risk preview
Management guided for 25% year-on-year revenue growth in FY27, consistent with historical performance.
Ongoing conflict in the Gulf region has disrupted feedstock supply chains and pushed raw material prices higher, potentially impacting margins.
View Risks →